CN115414349A - 芹菜素在制备治疗猫鼻支气管炎药物中的用途 - Google Patents
芹菜素在制备治疗猫鼻支气管炎药物中的用途 Download PDFInfo
- Publication number
- CN115414349A CN115414349A CN202211037573.2A CN202211037573A CN115414349A CN 115414349 A CN115414349 A CN 115414349A CN 202211037573 A CN202211037573 A CN 202211037573A CN 115414349 A CN115414349 A CN 115414349A
- Authority
- CN
- China
- Prior art keywords
- apigenin
- feline
- rhinobronchitis
- cell
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 title claims abstract description 43
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229940117893 apigenin Drugs 0.000 title claims abstract description 43
- 235000008714 apigenin Nutrition 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 241000282324 Felis Species 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims abstract description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 42
- 241000700605 Viruses Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 14
- 239000012528 membrane Substances 0.000 description 12
- 241000282326 Felis catus Species 0.000 description 11
- 238000005406 washing Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241001455646 Buffalopox virus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了芹菜素在制备治疗猫鼻支气管炎药物中的用途,属于生物医药领域。本发明通过实验验证了,芹菜素可以抑制猫疱疹病毒,并且随芹菜素浓度增加,对猫疱疹病毒抑制作用增强,最低有效浓度为10.3μM。因此,芹菜素可以应用到治疗猫鼻支气管炎中,为猫鼻支气管炎的治疗提供了新的途径。
Description
技术领域
本发明涉及生物医药领域,特别是涉及芹菜素在制备治疗猫鼻支气管炎药物中的用途。
背景技术
猫鼻支气管炎是由猫疱疹病毒(FHV-1)感染所引起的一类急性、高度接触性传染病,潜伏期一般为2-6d,兽医临床上主要以感染猫呼吸道感染症状、角膜结膜炎及流产为特征;感染初期病猫出现精神沉郁、流清亮鼻液、打喷嚏、咳嗽和浆液性眼睛分泌物增多;猫疱疹病毒1(FHV-1;猫科动物疱疹病毒1(FeHV-1))是疱疹病毒亚科的静脉曲张病毒属的一员。和家猫一样,FeHV-1还感染了猫科动物的其他一些成员。幼猫发病率可达100%,死亡率50%,成年猫死亡率很低,是猫的重要呼吸道疾病之一,自然条件下经呼吸道和消化道感染,也可通过飞沫迅速传播。该病毒目前只有一种血清型被确认,猫感染后,病毒能在病猫鼻腔、咽喉、气管、结膜和舌上皮细胞内繁殖,并随其分泌物排到体外。有些猫感染后不呈现症状,称为隐性感染,但仍能向外排出病毒。因此,当健康猫接触了被病毒污染的饲料、水、用具和周围环境时,就可引起本病传播。
芹菜素是在蔬菜和水果中发现的许多天然类黄酮之一,例如芹菜、欧芹、洋葱、茶和葡萄柚。黄酮类化合物可作为抗氧化剂,通过自由基介导的反应保护生物分子免受氧化损伤。据报道,芹菜素在与氧化过程相关的疾病中发挥保护作用,例如心血管和神经系统疾病。芹菜素通过调节脂多糖(LPS-)诱导的心肌损伤模型中的氧化应激和炎症来减轻心肌毒性。据报道,芹菜素可以在体外抑制非洲猪瘟病毒,同时芹菜素显示出对水牛痘病毒(BPXV)具有很强的体外和卵内抗病毒功效。
查阅相关资料可知,目前仍未见芹菜素在猫疱疹病毒方面的相关报道。因此,将芹菜素引入抑制猫疱疹病毒中,具有重大现实意义。
发明内容
本发明的目的是提供芹菜素在制备治疗猫鼻支气管炎药物中的用途,以解决上述现有技术存在的问题,芹菜素能有效抑制猫疱疹病毒,可以应用到猫鼻支气管炎的治疗药物中。
为实现上述目的,本发明提供了如下方案:
本发明提供芹菜素或其衍生物或其药学上可接受的盐在制备治疗猫鼻支气管炎药物中的用途。
本发明还提供芹菜素或其衍生物或其药学上可接受的盐在制备抑制猫疱疹病毒感染药物中的用途。
优选的是,所述治疗猫鼻支气管炎药物或所述抑制猫疱疹病毒感染药物还包括辅料。
本发明公开了以下技术效果:
本发明通过实验验证了,芹菜素可以抑制猫疱疹病毒,并且随芹菜素浓度增加,对猫疱疹病毒抑制作用增强,最低有效浓度为10.3μM。因此,芹菜素可以应用到治疗猫鼻支气管炎中,为猫鼻支气管炎的治疗提供了新的途径。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为芹菜素及其衍生物在细胞水平对病毒的抑制效果;其中,A为细胞对照,B为猫疱疹病毒感染CCL-94 48h后病变图片,C为将芹菜素加入感染细胞后细胞感染图片;
图2为芹菜素及其衍生物对细胞毒性作用的CC50的测定;
图3为芹菜素抗病毒活性间接免疫荧光测定;其中,***代表有极其显著统计学差异;
图4为芹菜素及其衍生物抗病毒活性TCID50的测定;其中,Postive CCL-94组为猫疱疹病毒感染猫肾细胞,negative组为猫肾细胞对照;
图5为芹菜素及其衍生物抗病毒活性EC50的测定;
图6为芹菜素及其衍生物抗病毒活性Western Blot鉴定。
具体实施方式
现详细说明本发明的多种示例性实施方式,该详细说明不应认为是对本发明的限制,而应理解为是对本发明的某些方面、特性和实施方案的更详细的描述。
应理解本发明中所述的术语仅仅是为描述特别的实施方式,并非用于限制本发明。另外,对于本发明中的数值范围,应理解为还具体公开了该范围的上限和下限之间的每个中间值。在任何陈述值或陈述范围内的中间值以及任何其他陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。
除非另有说明,否则本文使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料,但是在本发明的实施或测试中也可以使用与本文所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入,用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时,以本说明书的内容为准。
在不背离本发明的范围或精神的情况下,可对本发明说明书的具体实施方式做多种改进和变化,这对本领域技术人员而言是显而易见的。由本发明的说明书得到的其他实施方式对技术人员而言是显而易见的。本申请说明书和实施例仅是示例性的。
关于本文中所使用的“包含”、“包括”、“具有”、“含有”等等,均为开放性的用语,即意指包含但不限于。
以下实施例中的病毒为猫疱疹病毒,来源于武汉科前生物股份有限公司实验室;猫肾细胞(CCL-94)来源于ATCC(编号bio-68358)购买;芹菜素购自MCE,产品纯度>99%。
实施例1芹菜素对细胞活性的检测
1)取生长状态良好的CCL-94细胞进行消化传代,用细胞生长液调整细胞密度为1×105/mL,接种于96孔板,每孔100μL,置于37℃、5%CO2培养箱培养14h;
2)14h后,取出96孔板,弃去孔中培养基,用无菌PBS清洗三次;
3)将芹菜素及其衍生物用细胞维持液稀释成100μM、50μM、25μM、12.5μM和6.25μM,然后依次加入到CCL-94细胞中,并用一纵列加入100μL细胞维持液做为对照;
4)48h后,用MTS试剂进行细胞活力检测。
如图1所示,镜下可以观察到正常的CCL-94细胞生长状态良好,形态完整,界限清晰。而用病毒接种感染的CCL-94细胞,3天后出现细胞变圆,皱缩出现“葡萄串”样病变,病变非常明显。用芹菜素及其衍生物和病毒同时处理细胞后,细胞界病变细胞变圆,皱缩明显减少,细胞生长较好。
测定细胞存活率能反应芹菜素及其衍生物对细胞的毒性作用,根据公式计算出细胞存活率(%)=经过化合物处理的细胞发光值平均值/细胞对照组发光值平均值。芹菜素及其衍生物对CCL94细胞的毒性作用较小,其CC50大于50μM(如图2所示)。
实施例2芹菜素对病毒活性TCID50的测定
1)将CCL-94细胞进行消化传代,用细胞生长液调整细胞密度为1×105/mL,接种12孔板1mL/孔,37℃、5%CO2培养箱培养14h;
2)14h后,取出12孔板,做好标记,分别为20μM、10μM、5μM、2.5μM、1.25μM和0.625μM;准备EP管,加入细胞维持液与化合物,使其终浓度为上述5个浓度,振荡器上混匀至少5s;
3)弃去12孔板孔中培养基,用无菌PBS清洗三次,甩干后加入已经稀释好的化合物;置于37℃、5%CO2培养箱孵育1h;
4)1h后,取出12孔板,每孔接种0.01MOI的病毒,轻晃12孔板混匀,每块12孔板设置病毒对照与细胞对照;于37℃、5%CO2培养箱培养;
5)48h后,病毒对照出现70%病变,将12孔板转移至-80℃超低温冰箱冻融一次;
6)收集每孔液体至EP管中,4000rpm离心10min后收集上清测毒价;
7)准备生长状态良好的细胞,待长到80%左右后用胰酶消化,铺到96孔板中。
8)待96孔板中的细胞长到80%左右时,将病毒在灭菌的2mL EP管中进行10倍倍比稀释(首次用10-1到10-12),每孔病毒悬液量为100μL,每个稀释度作8孔,并做好对照孔;
9)操作需在冰上进行,保证毒价的稳定,并且要震荡均匀,防止病毒聚团,导致测出的毒价偏差较大;
10)平稳地将96板移至含有5%CO2,37℃细胞培养箱;
11)48h后观察结果,取出96孔板在显微镜上看细胞病变,并记录结果;
12)按Reed和Muench两氏法计算病毒TCID50。
如图3所示,芹菜素及其衍生物在20μM、10μM、5μM、2.5μM、1.25μM、0.6125μM和0μM时,TCID50分别为10-1.44/mL、10-2.62/mL、10-3.96/mL、10-6.51/mL、10-6.94/mL、10-7.42/mL;如图所示在10μM可以下降4.02个滴度。
实施例3芹菜素对病毒活性的间接免疫荧光检测
1)取生长状态良好的CCL-94细胞进行消化传代,用细胞生长液调整细胞密度为1×105/mL,接种于96孔板100μL/孔,置于37℃、5%CO2培养箱培养12h;
2)12h后细胞长满单层,取出96孔板用无血清DMEM培养基清洗两遍,换成细胞维持液,加入化合物进行2倍倍比稀释,同时加入0.01MOI病毒液,使化合物终浓度为25μM、12.5μM、6.26μM、3.125μM、1.5625μM、和0.78125μM,同时设置病毒对照组和细胞对照组;
3)待细胞出现60%病变,弃掉孔中培养基,用PBS清洗2遍后加入4%多聚甲醛室温作用10min;
4)弃掉废液,用PBS洗2次后加入含1%BSA的PBST的封闭液,在37℃静置作用1h;
5)PBS洗2次后加入1:1000稀释的阳性血清,37℃静置作用1h;
6)PBST洗4次后加入1:2000加入羊抗兔荧光二抗,37℃避光静置作用1h;
7)弃掉二抗,用PBS洗4次,置于荧光显微镜下观察拍照。
如图4所示,可以看出芹菜素及其衍生物在20μM时,基本没检测到猫疱疹病毒。随着药物浓度的下降,检测到的猫疱疹病毒不断增加,在2.5μM时,可以在细胞中检测到大量的猫疱疹病毒。
实施例4芹菜素对病毒活性Western Blot的测定
1)待细胞病变约70%,先弃掉细胞培养液,用预冷的PBS洗一次细胞,吸干PBS后,再用1mL(6孔板)的PBS重悬细胞,装入2mL的EP管中;
2)4℃4000r/min离心5min,弃掉上清,加入120μL(6孔板)的细胞裂解液,重悬,在4℃旋转作用25min;
3)4℃12000r/min离心20min,收集上清,加入5×loading buffer,沸水中煮10min后冰上10min,4℃保存;
4)制备12%分离胶,混匀后加入玻璃板中,并在分离胶上加入一层去离子水,置于通风橱中室温放置30min左右;
5)待分离胶完全聚合后,将配制好的5%的浓缩胶加入分离胶之上,插入梳子,于通风橱中室温放置30min左右;
6)将配制好的聚丙烯酰胺凝胶置于垂直电泳槽中,往中间槽及外槽加入适量的1×SDS-PAGE电泳缓冲液,于点样孔中加入适量体积的处理好的蛋白样品和蛋白Marker;
7)接上电源80V 30mim,再120V 1h20min进行电泳;
8)转膜:SDS-PAGE电泳结束后,根据目的蛋白的分子量,以蛋白Marker为对照进行切胶并裁剪合适大小的滤纸和PVDF膜。将切好的滤纸放入电转缓冲液中,将切好的PVDF膜放入甲醇中浸泡,然后分别放入纯水和电转缓冲液中浸泡,放入转膜槽中以120V电压转膜,根据蛋白大小,转膜时间60min;
9)封闭:轻轻用镊子将膜转入一个干净的平皿内,加入适量的封闭液(5%脱脂牛奶),置于摇床温育2h;
10)一抗孵育:将膜用TBST涮洗一下,放入含事先稀释好一抗的平皿中,于室温摇床上孵育2.5h;
11)二抗孵育:将膜用TBST洗3次,每次15min,然后将膜放入含事先稀释好二抗的平皿中,于室温摇床上孵育2h,孵育完后将膜用TBST洗六遍,每次5min;
12)显色:将A液和B液等体积混匀,于显色仪器中显色;
13)显色拍照后用TBST将膜清洗六遍,每次5min。同样方法孵育GAPDH一抗与羊抗兔二抗,显色后拍照保存。
半最大效应浓度(EC50)能反应芹菜素及其衍生物对病毒的抑制效果,即能达到50%最大生物效应(抑制病毒)对应的药物浓度。结果如图5所示,由EC50曲线图可知芹菜素及其衍生物对猫疱疹病毒的治疗效果很好,EC50的具体数值为10.3μM。
如图6所示,可以看出随着药物浓度增加,细胞中检测到的病毒蛋白量不断减少,有明显剂量依耐性。在20μM药物浓度下,基本检测不到病毒蛋白。
以上所述的实施例仅是对本发明的优选方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案做出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
Claims (3)
1.芹菜素或其衍生物或其药学上可接受的盐在制备治疗猫鼻支气管炎药物中的用途。
2.芹菜素或其衍生物或其药学上可接受的盐在制备抑制猫疱疹病毒感染药物中的用途。
3.如权利要求1或2所述的应用,其特征在于,所述治疗猫鼻支气管炎药物或所述抑制猫疱疹病毒感染药物还包括辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211037573.2A CN115414349B (zh) | 2022-08-26 | 2022-08-26 | 芹菜素在制备治疗猫鼻支气管炎药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211037573.2A CN115414349B (zh) | 2022-08-26 | 2022-08-26 | 芹菜素在制备治疗猫鼻支气管炎药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115414349A true CN115414349A (zh) | 2022-12-02 |
CN115414349B CN115414349B (zh) | 2023-11-03 |
Family
ID=84200377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211037573.2A Active CN115414349B (zh) | 2022-08-26 | 2022-08-26 | 芹菜素在制备治疗猫鼻支气管炎药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115414349B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1258191A (zh) * | 1997-03-26 | 2000-06-28 | 梅里尔·斯奎尔斯 | 人免疫缺陷病毒和其它传染性疾病的抗微生物预防和治疗 |
US6399654B1 (en) * | 1995-06-23 | 2002-06-04 | Advanced Life Sciences, Inc. | Biflavanoids and derivatives thereof as antiviral agents |
US6555523B1 (en) * | 1999-07-08 | 2003-04-29 | Patrick T. Prendergast | Use of cirsiliol and derivatives to treat infections |
CN1739597A (zh) * | 2005-07-12 | 2006-03-01 | 东北林业大学 | 一种具有抗疱疹病毒活性的木豆提取物 |
CN101108200A (zh) * | 2006-04-21 | 2008-01-23 | 朱耕新 | 繁缕磺酸或硫酸多糖酯总酚苷组合物及其制备方法和抗病毒应用 |
KR20160012528A (ko) * | 2014-07-24 | 2016-02-03 | 고려대학교 산학협력단 | 감마 허피스바이러스 감염의 개선 및 치료에 사용하기 위한 아카세틴 및 아피제닌의 용도 |
CN105555954A (zh) * | 2013-03-14 | 2016-05-04 | 伊佩尤斯生物技术公司 | 改进的胸苷激酶基因 |
-
2022
- 2022-08-26 CN CN202211037573.2A patent/CN115414349B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399654B1 (en) * | 1995-06-23 | 2002-06-04 | Advanced Life Sciences, Inc. | Biflavanoids and derivatives thereof as antiviral agents |
US20020068757A1 (en) * | 1995-06-23 | 2002-06-06 | Advanced Life Sciences, Inc. | Biflavanoids and derivatives thereof as antiviral agents |
CN1258191A (zh) * | 1997-03-26 | 2000-06-28 | 梅里尔·斯奎尔斯 | 人免疫缺陷病毒和其它传染性疾病的抗微生物预防和治疗 |
US6555523B1 (en) * | 1999-07-08 | 2003-04-29 | Patrick T. Prendergast | Use of cirsiliol and derivatives to treat infections |
CN1739597A (zh) * | 2005-07-12 | 2006-03-01 | 东北林业大学 | 一种具有抗疱疹病毒活性的木豆提取物 |
CN101108200A (zh) * | 2006-04-21 | 2008-01-23 | 朱耕新 | 繁缕磺酸或硫酸多糖酯总酚苷组合物及其制备方法和抗病毒应用 |
CN105555954A (zh) * | 2013-03-14 | 2016-05-04 | 伊佩尤斯生物技术公司 | 改进的胸苷激酶基因 |
KR20160012528A (ko) * | 2014-07-24 | 2016-02-03 | 고려대학교 산학협력단 | 감마 허피스바이러스 감염의 개선 및 치료에 사용하기 위한 아카세틴 및 아피제닌의 용도 |
Non-Patent Citations (3)
Title |
---|
LIEN-CHAI CHIANG,等: "Antiviral activities of extracts and selected pure constituents of Ocimum basilicum", CLIN EXP PHARMACOL PHYSIOL, vol. 32, no. 10, pages 813 - 412 * |
孙斌, 瞿伟菁, 张晓玲: "芹菜素的药理作用研究进展", 中药材, no. 07, pages 65 - 68 * |
王海娣;刘艾林;杜冠华;: "芹菜素药理作用的研究进展", 中国新药杂志, no. 18, pages 15 - 19 * |
Also Published As
Publication number | Publication date |
---|---|
CN115414349B (zh) | 2023-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jung et al. | Herpesviral haematopoietic necrosis of goldfish, Carassius auratus (L.) | |
Carrascosa et al. | Production and titration of African swine fever virus in porcine alveolar macrophages | |
Hoorn et al. | On the growth of certain “newer” respiratory viruses in organ cultures | |
KR20000029968A (ko) | 바이러스증식을위한불멸화된세포주 | |
CN110063954B (zh) | Fhpi在制备治疗猫传染性腹膜炎药物中的应用 | |
Cubillos et al. | Characterisation of strains of infectious bronchitis virus isolated in Chile | |
CN110368490B (zh) | 貉细小病毒性肠炎、犬瘟热二联灭活疫苗及其制备方法 | |
CN103952369B (zh) | 一株草鱼鱼鳔上皮样细胞系及其应用 | |
CN111973600B (zh) | 霉酚酸或其衍生物在制备犬瘟热病毒抑制剂中的用途 | |
Bouquet et al. | Isolation and characterisation of an adenovirus isolated from Muscovy ducks | |
CN115414349A (zh) | 芹菜素在制备治疗猫鼻支气管炎药物中的用途 | |
CN113755438B (zh) | 一种鳜鱼脊髓组织细胞系及其构建方法与应用 | |
CN110129272A (zh) | 稳定表达map3k8蛋白的pk-15细胞株及其构建和应用 | |
CN112126619B (zh) | 弹状病毒敏感的黄鳝肾组织细胞系及应用 | |
CN104911153A (zh) | 一种分离禽偏肺病毒的方法 | |
Eidson et al. | Studies on acute Marek's disease. XI. Propagation of the GA isolate of Marek's disease in tissue culture | |
CN115414366B (zh) | 11-酮基-beta-乳香酸在制备治疗猫杯状病毒病的药物中的应用 | |
CN114107171A (zh) | 鹅视网膜上皮细胞系及其构建方法与应用 | |
Dannevig et al. | The first isolation of a rhabdovirus from perch (Perca fluviatilis) in Norway | |
CN114984006B (zh) | 3,3`-二吲哚甲烷在制备治疗猫传染性腹膜炎的药物中的应用 | |
CN115282154A (zh) | 11-羰基-β-乙酰乳香酸在制备治疗猫传腹药物中的用途 | |
CN113234660A (zh) | 一种草鱼输尿管组织细胞系及其应用 | |
CN113249298A (zh) | 一种草鱼动脉球组织细胞系及其应用 | |
CN107982323B (zh) | 矮紫堇在制备抑制和杀灭牛病毒性腹泻病毒bvdv药物中的应用 | |
CN117904032B (zh) | 一株海鲈鳍条细胞系及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |